Alex Hongsheng Chang

9PUBLICATIONS
36CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 08, 2026
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.

|Jul 03, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

|Mar 27, 2026
Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Fan Yang, Rui Liu, Zhonghua Fu

|Feb 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Wenqiang Yan, Chenxing Du, Rui Lv

|Sep 24, 2025
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Jingjing Feng, Dawei Huo, Ruimin Hong

|Mar 28, 2024
Author Correction: CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.

Yongxian Hu, Jingjing Li, Fang Ni

Pageof 2

Frequent Collaborators

5 joint publications

He Huang

3 joint publications

Yongxian Hu

2 joint publications

Jingjing Li

2 joint publications

Marcel R M van den Brink